The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. The first thing we can say based on these data, is that when you are offered the second dose, please also take that because its very important. The study was not set up to look at any differences between the two. The numbers were very small and there was uncertainty over their significance, said the researchers. That rose to more than 85% after the second dose.
The Publigencia study was not formally conducted.
( z0 conduct :ARG1 ( z1 study :mod ( z2 government-organization :name ( z3 name :op "Publigencia" ) ) ) :manner ( z4 formal ) :polarity - )
(z0 / conduct-01
    :ARG1 (z1 / study
              :mod (z2 / government-organization
                       :name (z3 / name
                                 :op1 "Publigencia")))
    :manner (z4 / formal)
    :polarity -)
The Publigencia study was not formally conducted .
z2 :name z3
z3 :op1 1
z1 :mod z2
z0 :manner z4
z0 :polarity 0
z0 :ARG1 z1